# OnCo record pd-l1-assay-discordance (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/pd-l1-assay-discordance/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "pd-l1-assay-discordance" ;
  schema:name "PD-L1 assay discordance (SP142, SP263 and 22C3 in breast cancer)"@en ;
  schema:alternateName "PD-L1 assay comparison"@en, "SP142 versus 22C3"@en, "PD-L1 antibody clones"@en, "PD-L1 test harmonisation"@en, "Non-interchangeable PD-L1 assays"@en ;
  schema:description "Three commercial PD-L1 stains give different answers on the same breast tumour: the SP142 assay used with atezolizumab called fewer than half of tumours positive while the 22C3 and SP263 assays called about three quarters. Because the pembrolizumab licence rests on 22C3 combined positive score 10, which test a laboratory runs, and how it scores it, decides who is offered immunotherapy."@en ;
  schema:url <https://onco.cc/terms/pd-l1-assay-discordance/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/PD-L1> ;
  schema:citation <https://doi.org/10.1093/jnci/djab108>, <https://doi.org/10.1056/nejmoa1809615>, <https://doi.org/10.1016/s0140-6736(20)32531-9>, <https://www.nice.org.uk/guidance/ta801> ;
  onco:tag "breast", "tnbc" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/atezolizumab/> ;
  onco:terms <https://onco.cc/terms/pd-l1-cps-10-tnbc/>, <https://onco.cc/terms/cps/> ;
  onco:trials <https://onco.cc/trials/impassion130/>, <https://onco.cc/trials/keynote-355/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/> .